Shots:
Biohaven has granted SK Biopharmaceuticals exclusive worldwide rights to its Kv7 ion channel platform, led by opakalim (BHV-7000), a P-II/III candidate for focal epilepsy, with RISE3 topline results are expected in H2’26
Biohaven will receive upfront & milestone payments up to $795M for the Kv7 platform, incl. $400M in cash ($350M at closing &…
